Spyglass Pharma, Inc. (NASDAQ:SGP - Free Report) - Analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for Spyglass Pharma in a research note issued on Thursday, November 12th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($2.76) per share for the year, down from their prior estimate of ($2.52). HC Wainwright currently has a "Buy" rating and a $43.00 target price on the stock. The consensus estimate for Spyglass Pharma's current full-year earnings is ($2.77) per share. HC Wainwright also issued estimates for Spyglass Pharma's Q4 2026 earnings at ($0.75) EPS, Q1 2027 earnings at ($0.69) EPS, Q3 2027 earnings at ($0.65) EPS, Q4 2027 earnings at ($0.66) EPS and FY2027 earnings at ($2.64) EPS.
Spyglass Pharma (NASDAQ:SGP - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.07).
Several other equities analysts also recently issued reports on the stock. Stifel Nicolaus upped their price objective on shares of Spyglass Pharma from $42.00 to $44.00 and gave the company a "buy" rating in a report on Friday. Wall Street Zen raised shares of Spyglass Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, October 31st. UBS Group reiterated a "buy" rating on shares of Spyglass Pharma in a research note on Monday, October 5th. Citigroup boosted their target price on shares of Spyglass Pharma from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Weiss Ratings upgraded shares of Spyglass Pharma from a "sell (e)" rating to a "sell (d-)" rating in a research note on Friday. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $45.83.
Read Our Latest Analysis on Spyglass Pharma
Spyglass Pharma Stock Performance
Spyglass Pharma stock opened at $32.88 on Monday. The stock has a 50-day moving average of $28.78 and a two-hundred day moving average of $24.83. Spyglass Pharma has a one year low of $17.06 and a one year high of $39.92. The stock has a market cap of $1.10 billion and a PE ratio of -4.25.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the company. First Light Asset Management LLC acquired a new position in Spyglass Pharma in the 1st quarter worth approximately $9,716,000. Affinity Asset Advisors LLC purchased a new position in Spyglass Pharma during the 1st quarter worth approximately $6,478,000. Monashee Investment Management LLC acquired a new stake in Spyglass Pharma during the 1st quarter valued at approximately $2,461,000. Bank of America Corp DE acquired a new stake in Spyglass Pharma during the 1st quarter valued at approximately $726,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Spyglass Pharma in the 2nd quarter valued at $533,000.
About Spyglass Pharma
(
Get Free Report)
SpyGlass Pharma is a clinical-stage ophthalmology company developing sustained-release drug delivery systems for chronic eye diseases. Its research is focused on reducing reliance on patients' regular use of eye drops. The company's lead program is a bimatoprost drug delivery system being developed to treat glaucoma and ocular hypertension. Bimatoprost is a medication used to lower eye pressure, and SpyGlass is studying a delivery approach intended to provide treatment over an extended period. SpyGlass Pharma's work centers on advancing this ophthalmic delivery platform and its lead program through clinical development.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Spyglass Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyglass Pharma wasn't on the list.
While Spyglass Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.